Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
OBJECTIVE
High doses of flutamide, which is the only antiandrogen that specifically blocks the androgen receptor, have recently been used with good clinical results in women with hirsutism. Since regression of hair growth requires long-term therapy, clinical and economic considerations are important. The use of the lowest efficacious dosage could reduce costs. This study was undertaken to compare safety and efficacy of a low dose of flutamide (125 mg twice daily) alone and in combination with a triphasic oral contraceptive (OC) in women with idiopathic hirsutism.


METHODS
Flutamide was administered orally in a low dose of 125 mg twice daily for 12 months alone in women with no risk of pregnancy or during the use of an oral contraceptive.


METHODS
Women were seen every 3 months and were evaluated for hirsutism score, hormone and lipid measurements.


METHODS
The study, which was conducted as a prospective open trial, was proposed to patients with idiopathic hirsutism, that is, with serum androgen levels in normal range and LH/FSH ratio less than 2.


RESULTS
A statistically significant decrease in hirsutism score as compared to baseline was observed after only 3 months with either treatment, flutamide alone (16.9 +/- 1.6 vs 14.2 +/- 1.7, P < 0.0001) or the combination of flutamide with OC (15.6 +/- 0.8 vs 11.9 +/- 0.8, P < 0.001). Three months after cessation of treatment a statistically significant decrease from baseline was observed in the two groups. Nevertheless, at 6 months post-treatment this decrease was still significant only in the group who took flutamide in combination with an oral contraceptive. Flutamide alone does not appear to modify the levels of lipoproteins. The association of flutamide with a triphasic formulation significantly increased the HDL-C levels.


CONCLUSIONS
This study shows beneficial effects of a low dose of flutamide in women with idiopathic hirsutism. The addition of an oral contraceptive is judicious to prevent pregnancy and reduce recurrence of hirsutism after cessation of flutamide. Peripheral androgenic blockage does not modify lipid profiles and it might reduce the negative effect of oral contraceptive on HDL-C levels. The addition of electrolysis delays the recurrence of hirsutism after cessation of flutamide.
Dodin
S
S
Centre de Recherche, Hôpital St-François d'Assise, Québec, Canada.
Faure
N
N
Cédrin
I
I
Méchain
C
C
Turcot-Lemay
L
L
Guy
J
J
Lemay
A
A
D000328:Adult; D000726:Androgen Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D003278:Contraceptives, Oral, Hormonal / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D005485:Flutamide / Q000008:administration & dosage* / Q000627:therapeutic use; D012739:Gonadal Steroid Hormones / Q000097:blood; D006628:Hirsutism / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D009644:Norgestrel / Q000627:therapeutic use*; D011446:Prospective Studies
D000726:Androgen Antagonists; D003278:Contraceptives, Oral, Hormonal; D012739:Gonadal Steroid Hormones; D009644:Norgestrel; D004997:Ethinyl Estradiol; D005485:Flutamide; D019304:Ethinyl Estradiol-Norgestrel Combination